Takeda is halting Phase III trials of severe sepsis treatment TAK-242 and abandoning development of the drug following a development strategy review. "Takeda has concluded that TAK-242's profile does not meet the criteria to support continuation of further development activities. This decision has not been influenced by any concerns over the safety or efficacy of the compound," the company said in a brief statement. Takeda release